Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Sunitinib and pancreatic neuroendocrine tumours. More assessment needed.

[No authors listed]

Prescrire Int. 2012 May;21(127):123-5. Review.

PMID:
22827001
[PubMed - indexed for MEDLINE]
2.

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

Adams VR, Leggas M.

Clin Ther. 2007 Jul;29(7):1338-53. Review.

PMID:
17825686
[PubMed - indexed for MEDLINE]
3.

Sunitinib in pancreatic neuroendocrine tumors.

Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S.

Target Oncol. 2012 Jun;7(2):117-25. doi: 10.1007/s11523-012-0220-2. Epub 2012 Jun 2. Review.

PMID:
22661319
[PubMed - indexed for MEDLINE]
4.

Sunitinib.

Deeks ED, Keating GM.

Drugs. 2006;66(17):2255-66; discussion 2267-8. Review.

PMID:
17137406
[PubMed - indexed for MEDLINE]
5.

Sunitinib for the management of advanced renal cell carcinoma.

Escudier B.

Expert Rev Anticancer Ther. 2010 Mar;10(3):305-17. doi: 10.1586/era.10.26. Review.

PMID:
20214511
[PubMed - indexed for MEDLINE]
6.

Sunitinib for advanced pancreatic neuroendocrine tumors.

Hubner RA, Valle JW.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1817-27. doi: 10.1586/era.11.171. Review.

PMID:
22117148
[PubMed - indexed for MEDLINE]
7.

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Theou-Anton N, Faivre S, Dreyer C, Raymond E.

Drug Saf. 2009;32(9):717-34. doi: 10.2165/00002018-200932090-00003. Review.

PMID:
19670913
[PubMed - indexed for MEDLINE]
8.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Hiles JJ, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661. Review.

PMID:
18192256
[PubMed - indexed for MEDLINE]
9.

Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.

Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.

J Oncol Pharm Pract. 2007 Mar;13(1):5-15. Review.

PMID:
17621562
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.

Bisht S, Feldmann G, Brossart P.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):777-88. doi: 10.1517/17425255.2013.791281. Epub 2013 Apr 16. Review.

PMID:
23590356
[PubMed - indexed for MEDLINE]
11.

New targeted agents in gastroenteropancreatic neuroendocrine tumors.

Benavent M, de Miguel MJ, Garcia-Carbonero R.

Target Oncol. 2012 Jun;7(2):99-106. doi: 10.1007/s11523-012-0218-9. Epub 2012 May 15. Review.

PMID:
22585431
[PubMed - indexed for MEDLINE]
12.

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.

Clin Cancer Res. 2007 Mar 1;13(5):1367-73. Review.

PMID:
17332278
[PubMed - indexed for MEDLINE]
Free Article
13.

Sunitinib: from rational design to clinical efficacy.

Chow LQ, Eckhardt SG.

J Clin Oncol. 2007 Mar 1;25(7):884-96. Review.

PMID:
17327610
[PubMed - indexed for MEDLINE]
Free Article
14.

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.

Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S87-94. doi: 10.1016/S0305-7372(10)70026-8. Review.

PMID:
21129617
[PubMed - indexed for MEDLINE]
15.

Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.

Ravaud A, Bello CL.

Anticancer Drugs. 2011 Jun;22(5):377-83. doi: 10.1097/CAD.0b013e3283442039. Review.

PMID:
21394020
[PubMed - indexed for MEDLINE]
16.

Sunitinib in solid tumors.

Gan HK, Seruga B, Knox JJ.

Expert Opin Investig Drugs. 2009 Jun;18(6):821-34. doi: 10.1517/13543780902980171. Review.

PMID:
19453268
[PubMed - indexed for MEDLINE]
17.

Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib.

Blay JY.

Ann Oncol. 2010 Feb;21(2):208-15. doi: 10.1093/annonc/mdp291. Epub 2009 Aug 12. Review.

PMID:
19675092
[PubMed - indexed for MEDLINE]
Free Article
18.

Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.

Cabebe E, Wakelee H.

Drugs Today (Barc). 2006 Jun;42(6):387-98. Review.

PMID:
16845442
[PubMed - indexed for MEDLINE]
19.

Sunitinib for the treatment of metastatic renal cell carcinoma.

Oudard S, Beuselinck B, Decoene J, Albers P.

Cancer Treat Rev. 2011 May;37(3):178-84. doi: 10.1016/j.ctrv.2010.08.005. Review.

PMID:
20817406
[PubMed - indexed for MEDLINE]
20.

Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.

Wong MK, Jarkowski A.

Pharmacotherapy. 2009 Apr;29(4):473-8. doi: 10.1592/phco.29.4.473. Review.

PMID:
19323623
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk